A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after Allogeneic Hematopoietic Cell Transplantation (HCT)

Protocol No
DF-HCC-18-265-BOS
Principal Investigator
Saurabh Chhabra
Phase
II
Summary
Find out whether the new drug (ruxolitinib) reduces the symptoms of BOS, and whether it causes any problems (side effects).
Description
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after AlloHCT
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: